Economic Burden of Prostate Cancer in Iran: Measuring Costs and Quality of Life
Journal Title: Middle East Journal of Cancer - Year 2019, Vol 10, Issue 2
Abstract
Background: Prostate cancer (PCa) is the third most diagnosed cancer among men in Iran with approximately 4200 new cases in 2015. Considering the rapid growth of cancer diagnosis, this study aims to investigate the economic burden of PCa patients and their health-related quality of life (HRQoL) Methods: A retrospective survey was conducted on 500 registered patients to discover the pattern of care and distribution of patients in the main treatment categories. In the next step, a multi-center survey of the patients under treatment was conducted. The objective of this survey was to estimate direct medical costs (DMC), non-medical costs, and productivity losses for patients and family members. HRQoL was measured by the Functional Assessment of Cancer Therapy–Prostate questionnaire. Results: Despite high age of patients (72±9.25 years), only 53.3% of them were retired or disabled. The largest proportion of patients (54.3%) received medicinal or surgical hormone therapy. Radical prostatectomy was the main treatment for 31.7% of patients, 10.2% received radiation therapy, and 3.8% underwent chemotherapy. DMC for incident population was approximately 12.5 million US dollars/year, and the highest average cost per capita belonged to chemotherapy patients. Unpredictably, productivity loss was nearly as much as direct cost. The mean score for HRQoL was 0.62±0.16 for all patients. Orchiectomy group had the lowest HRQoL score (0.55±0.16). Chemotherapy patients suffered the worst scores in the physical well-being subscale (0.47±0.24). Hormone therapy patients had the least scores in the prostate-specific subscale (0.50±0.18). Conclusion: The economic burden of PCa is estimated approximately 25.8 million US dollars per year for incident population. When we refer to the high proportion of patients diagnosed in advanced state of the disease and higher per capita cost for these patients, policy makers should promote screening strategies to control health care costs and to increase both life expectancy and HRQoL.
Authors and Affiliations
Mohamad Javad Foroughi Moghadam Foroughi Moghadam, Mohsen Ayati, Maryam Rangchian, Gholamreza Pourmand, Peiman Haddad, Alireza Nikoofar, Hamidreza Rezvani, Jalil Hosseini, Jamshid Salamzadeh, Hamid Reza Rasekh
Keywords
Related Articles
- EP ID EP638889
- DOI 10.30476/mejc.2019.78519.
- Views 71
- Downloads 0
Predictors of Early Radiation Induced Esophageal Toxicity in Radiotherapy of Locally Advanced Non-small Cell Lung Cancer
Background: Radiation induced esophageal toxicity is a primary cause of treatment interruptions in the radiotherapy of lung cancer, for which there are no clear predictive factors. This study attempts to identify risk fa...
Small Cell Carcinoma of the Ovary: Report of a Case with Unusual and Aggressive Presentation
Small cell carcinoma of the ovary is an aggressive malignant tumor with no standard treatment. Despite surgery, chemotherapy and radiation, this tumor has a poor prognosis with rapid progression. The authors report a cas...
Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients
Background: This study aimed to assess several biochemical and oxidative stress parameters before and after radioiodine therapy in patients with well-differentiated thyroid cancer who consumed a low iodine diet and withd...
Relationship between MMP-11 Expression in Invasive Ductal Breast Carcinoma with its Clinicopathologic Parameters
Background: Breast cancer is one of the most common cancers in the world, particularly in Iran. There are many genomic and molecular factors that cause the occurrence of breast cancer. Many markers are associated with tu...
Adjuvant Chemotherapy of Early Stage Breast Cancer in Community-based Cancer Treatment Fields: CMF Compared with Anthracycline/Taxane-based Regimens
Introduction: Mortality rate of breast cancer has been fallen in recent years. Combination of cyclophosphamide, methotrexate, and 5-fluorouracil(CMF), as a pioneer of adjuvant chemotherapy of breast cancer, and later int...